Abstract
The native HIV-1 Tat protein was chosen as a vaccine candidate based on its key role in the virus life cycle and on the correlation of Tat-specific immune responses with the asymptomatic stage and lower disease progression rates, but also due to its sequence conservation amongst the various HIV clades as well as the adjuvant effects on dendritic cells. Safety, immunogenicity and efficacy data in monkeys support the development of this vaccine concept.
Publication types
-
Clinical Trial, Phase I
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AIDS Vaccines / adverse effects*
-
AIDS Vaccines / immunology
-
CD4 Lymphocyte Count
-
Double-Blind Method
-
HIV Antibodies / biosynthesis
-
HIV Infections / immunology*
-
HIV Infections / virology
-
HIV-1 / immunology*
-
Humans
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / immunology
-
Viral Load
-
tat Gene Products, Human Immunodeficiency Virus / adverse effects*
-
tat Gene Products, Human Immunodeficiency Virus / immunology
Substances
-
AIDS Vaccines
-
HIV Antibodies
-
Recombinant Proteins
-
tat Gene Products, Human Immunodeficiency Virus